← Home
Huberman Lab · June 1, 2026 · 2h 48m

Peptides: The Science, Uses & Safety

Dr. Abud Bakri
Show Notes

Dr. Abud Bakri, a board-certified internal medicine physician and peptide expert, discusses the history, mechanisms, clinical uses, and safety considerations of peptides including BPC-157, GHK-Cu, pinealon, epithalon, GLP-1s, and growth hormone-promoting peptides. The episode emphasizes the critical gap between animal and human data, the importance of sourcing from reputable compounding pharmacies versus gray and black markets, and the current regulatory and legal landscape surrounding peptide use. Bakri provides a grounded, cautious perspective on the promises and uncertainties of peptide medicine.

This summary was generated from show notes and public descriptions, not from a full transcript review. Details may contain inaccuracies.

Curious

•
BPC-157 Has Strong Animal Healing Data But Almost No Human Clinical Trials00:06:26
BPC-157 shows remarkable regenerative effects in animal models—healing tendon, muscle, nerve, and gut tissue—but human clinical evidence is sparse, creating a significant gap between preclinical promise and clinical reality.
ClaudeChatGPTGemini
•
Pinealon and Epithalon Come from Soviet Research with Unknown Long-Term Human Safety00:07:25
Pinealon and epithalon are peptides discovered in Soviet Russia claimed to improve sleep, cognition, and eye health, but long-term human safety data and Western clinical validation are minimal.
ClaudeChatGPTGemini

Highlights

•
Peptides Work via Specific Receptor Binding00:03:33
Peptides function by binding to specific cellular receptors, triggering downstream signaling cascades that produce biological effects; this receptor specificity is both their power and their limitation.
ClaudeChatGPTGemini
•
Angiogenesis Is Double-Edged: Necessary for Healing but Also Feeds Tumors00:41:32
Peptides that promote angiogenesis (new blood vessel growth) can accelerate tissue repair but may also inadvertently feed existing cancers by providing them with a blood supply.
ClaudeChatGPTGemini
•
FDA-Approved GLP-1s (Semaglutide, Tirzepatide) Carry Serious Risks Beyond Weight Loss00:29:41
GLP-1 receptor agonists like semaglutide and tirzepatide are FDA-approved for diabetes and weight loss but carry risks including pancreatitis, gastroparesis, gallbladder complications, and potential GI malignancy that users often don't understand.
ClaudeChatGPTGemini

Editorial

•
Compounding Pharmacies Vary Wildly in Quality and Testing Standards00:35:25
Peptides purchased from compounding pharmacies range from high-quality, rigorously tested products to contaminated or mislabeled preparations, with no consistent regulatory oversight.
ClaudeChatGPTGemini
•
The Peptide Field Is Built on Hype With Limited Human Validation00:03:33
The peptide market is characterized by extraordinary claims based primarily on animal data, while human clinical evidence is sparse, creating a gap between expectation and reality.
ClaudeChatGPTGemini

Misc

✧The peptide field is filled with hype; many claims rest on animal data without human validation.
✧Compounding pharmacies vary wildly in quality and testing standards.
✧Gray and black market peptides are often contaminated or mislabeled.
✧BPC-157 has strong animal data for healing but almost no human clinical trials.
✧Pinealon and epithalon were discovered in Soviet Russia; their long-term human safety is unknown.
✧GLP-1s (semaglutide, tirzepatide) have FDA approval but carry serious risks including pancreatitis and GI effects.
✧Angiogenesis (new blood vessel growth) is a double-edged sword—necessary for healing but also feeds tumors.
Was this useful?